The team’s central challenge was a familiar one in natural product research: essential oils are notoriously difficult to work with. They are poorly soluble in water, volatile, and prone to degradation, all of which limit how effectively they can be delivered to biological targets. To overcome this, the researchers turned to a self-nanoemulsifying approach, a formulation strategy in which the oil spontaneously forms tiny droplets when it encounters an aqueous environment. Span 80 and Tween 80, two widely used and well-characterized surfactants, served as the emulsifying agents that stabilize the resulting nanodroplets.

The optimization process identified a formulation with remarkably favorable physical characteristics. The optimal nanoemulsion had a mean particle size of 89.61 nanometers, small enough to navigate biological barriers that bulk oil droplets cannot. Equally important was its polydispersity index of 0.216, a measure of how uniform the droplet population is; values below 0.3 generally indicate a narrow and consistent size distribution, which is critical for reproducible pharmaceutical performance. The formulation also carried a zeta potential of -33.15 millivolts, a strongly negative surface charge that promotes electrostatic repulsion between droplets and helps prevent the particles from clumping together over time.

Confirmation came from atomic force microscopy, which visualized particles in the range of 30 to 150 nanometers, consistent with the dynamic measurements. Together, these results show that the system is not only small but physically stable, two prerequisites for any formulation intended for biological use. The self-nanoemulsifying design also means the system could, in principle, be administered as a concentrate that forms its own nanoemulsion upon contact with body fluids, simplifying manufacturing compared with approaches that require high-energy homogenization.

The antimicrobial results were striking. The nanoemulsion produced zones of inhibition measuring 53 millimeters against methicillin-resistant Staphylococcus aureus, the notorious hospital pathogen MRSA, 52 millimeters against susceptible S. aureus, and 48 millimeters against Proteus vulgaris. Perhaps most notable was the minimum inhibitory concentration: the formulation inhibited MRSA, S. aureus, P. vulgaris, Escherichia coli, and Klebsiella pneumoniae at just 0.19 micrograms per milliliter. Against a backdrop of rising antimicrobial resistance, the prospect of a plant-derived agent active against both Gram-positive and Gram-negative bacteria at such low concentrations is attracting significant attention.

The anticancer data were equally compelling. When tested across a panel of six cell lines, the optimized nanoemulsion showed lower IC50 values, meaning greater potency, than the crude essential oil in every case. The half-maximal inhibitory concentrations were 7.58 micrograms per milliliter for HeLa cervical cancer cells, 7.24 for Caco-2 colorectal adenocarcinoma cells, 8.23 for MCF-7 breast cancer cells, 10.02 for Hep-G2 liver cancer cells, 9.6 for B16-F7 melanoma cells, and 12.02 for LX-2 hepatic stellate cells. The corresponding values for the unformulated oil ranged from 12.08 to 18.1 micrograms per milliliter, meaning nanoemulsification improved potency by roughly 30 to 50 percent depending on the cell line.

Selectivity, however, is the metric that separates a promising lead from a laboratory curiosity, and here the study offered an encouraging signal. Against healthy HEK-293 kidney cells, the nanoemulsion’s IC50 was 2846.33 micrograms per milliliter, a concentration hundreds of times higher than those required to kill the cancer cells. This gap suggests that the formulation preferentially targets malignant cells over normal tissue, a property that many conventional chemotherapies lack. The authors caution that these are in vitro results, but the degree of preferential cytotoxicity provides a strong rationale for further investigation into how nanoscale delivery changes the way essential oil constituents interact with cell membranes.

The anti-inflammatory arm of the study added a third dimension. The oil demonstrated inhibitory activity against both cyclooxygenase enzymes, COX-1 and COX-2, which are central players in the inflammatory cascade and the targets of common painkillers such as ibuprofen. Notably, the oil showed greater selectivity for COX-2, the isoform more closely associated with inflammation and pain. COX-2 selectivity is pharmacologically desirable because inhibiting COX-1 is linked to gastrointestinal side effects, so a natural product with a COX-2 bias could inform the development of gentler anti-inflammatory agents, although enzyme-level activity does not guarantee efficacy in living organisms.

What makes this work scientifically interesting is not simply that oregano oil is bioactive, which has been known for decades, but that a straightforward formulation change amplified its activity so substantially. Researchers attribute such effects to improved dispersibility and enhanced contact between the oil’s lipophilic constituents and cell membranes. Nanosized droplets present an enormous surface area relative to their volume, increasing the rate at which active compounds partition into bacterial and cancer cell membranes. The surfactant shell may also facilitate uptake, and the negative surface charge can promote interaction with positively charged regions of microbial surfaces. While the precise mechanism remains to be fully elucidated, the pattern of enhanced activity across bacteria, cancer cells, and inflammatory targets is consistent with improved bioavailability at the cellular level.

The study, led by Ahmad M. Eid and colleagues at the Faculty of Pharmacy at An-Najah National University, stops short of clinical claims, and considerable work remains before any oregano-derived nanoformulation reaches patients. Safety pharmacology, in vivo efficacy, pharmacokinetics, and scale-up manufacturing all lie ahead. Yet the results demonstrate a practical principle with broad implications: self-nanoemulsification is a low-cost, solvent-free-friendly strategy for upgrading the performance of chemically characterized essential oils. As antimicrobial resistance accelerates and the search for selective anticancer agents intensifies, the humble oregano leaf, delivered in droplets a thousand times finer than a human hair, offers a vivid example of how nanotechnology can transform traditional natural products into credible candidates for modern medicine.

Subject of Research: Self-nanoemulsifying Origanum vulgare leaf oil system with antimicrobial, anticancer, and anti-inflammatory activities

Article Title: An investigation onto the potential antimicrobial, anticancer, and anti-inflammatory activities of a Origanum vulgare leaf oil self-nanoemulsifying system

Article References: Eid, A. M., Hawash, M., Al-Saleh, A., Hawash, B., Faqeeh, A., Hussein, A., & Hussein, S. (2026). An investigation onto the potential antimicrobial, anticancer, and anti-inflammatory activities of a Origanum vulgare leaf oil self-nanoemulsifying system. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05587-w

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05587-w

Keywords: Origanum vulgare, essential oil, nanoemulsion, self-nanoemulsifying system, antimicrobial, MRSA, anticancer, COX-2, anti-inflammatory, nanomedicine, drug delivery, natural products